Saildrone Closes $60M Financing to Bring Maritime Autonomy to Europe
Saildrone, the global leader in maritime autonomy, today announced the closing of a $60 million investment round led by EIFO, the Export and Investment Fund of Denmark. The investment will be used to bring Saildrone technology to Europe to address the urgent need for maritime security for critical infrastructure and wider defense applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513296505/en/
Four Saildrone Voyager uncrewed surface vehicles (USVs) will be deployed in Danish waters during the summer of 2025 in partnership with the Danish Armed Forces. The operational testing will begin in June and is part of a broader effort to integrate uncrewed systems into Denmark’s defense architecture.
The Baltic, North Sea, and European Arctic waters are currently facing unprecedented threats, and the need for persistent maritime domain awareness has never been greater. Saildrone’s extreme endurance unmanned surface vehicles utilize sophisticated sensors, combined with proprietary AI algorithms, to give a full picture of the maritime environment above and below the sea surface.
“I am thrilled to partner with EIFO and the Danish government to establish Saildrone’s European headquarters in Copenhagen, Denmark,” said Richard Jenkins, Saildrone’s founder and CEO. “Denmark’s unique geographic and political position at the heart of northern Europe makes it the perfect place to establish our European headquarters and operational hub. Working initially with the Danish Armed Forces, we plan to roll out Saildrone’s maritime intelligence services to multiple NATO countries during the course of the year. Our goal is to provide 24/7, year-round coverage for all critical infrastructure within the Baltic and North Sea, safeguarding these highly valuable installations for current and future generations.”
In addition to EIFO, other participants in the round included existing investors Lux Capital, Washington Harbor Partners, Crowley, and Academy Securities, joined by new investors Pinegrove, BZH Capital, What If Ventures, and Calm Ventures.
“We are thrilled to invest in Saildrone and subsequently that Denmark has been chosen as the center for Saildrone’s European activities. Saildrone is a leading company in a rapidly growing market, and gaining access to this technology can become critical for both Denmark’s and Europe’s security. We expect Saildrone will have an impact on both the Danish defense industry and the Danish challenges with surveillance in the Arctic and counteracting sabotage in Danish waters—at a fraction of the cost of a patrol ship,” said Peder Lundquist, CEO of EIFO.
Saildrone will deploy the first four Saildrone Voyagers in the Baltic Sea in June 2025, under contract to the Danish Armed Forces.
About Saildrone
Saildrone is a maritime defense and oceanographic survey company creating a paradigm shift in how navies, governments, and commercial organizations obtain the real-time, accurate data required to monitor the maritime domain. Powered primarily by renewable wind and solar energy, Saildrone’s fleet of unmanned surface vehicles (USVs) provides long-duration operations measured in months, not days. Saildrone USVs carry sophisticated sensors combined with proprietary AI algorithms to give a full picture of the maritime environment above and below the sea surface, supporting border protection, critical infrastructure security, and hydrographic survey. Saildrone has sailed more than 2,000,000 nautical miles from the High North to the Southern Ocean and spent over 50,000 days at sea in the harshest ocean conditions on the planet.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250513296505/en/
Contacts
Jenn Virskus
Director Marketing, Saildrone
Office: (510) 956-8361
jenn.virskus@saildrone.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press Release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press Release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press Release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press Release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom